William Blair Brokers Increase Earnings Estimates for NAMS

Key Points

• William Blair upgraded its earnings estimates for NewAmsterdam Pharma, projecting a Q3 2025 EPS of ($0.32), an increase from a previous estimate of ($0.52).
• NewAmsterdam Pharma's share price recently opened at $25.31, with a market cap of $2.84 billion and an average target price estimated at $41.20 among analysts.
• Institutional investors hold 89.89% of NewAmsterdam Pharma's stock, indicating strong institutional interest in the company amidst recent performances.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Equities researchers at William Blair raised their Q3 2025 EPS estimates for shares of NewAmsterdam Pharma in a note issued to investors on Wednesday, August 6th. William Blair analyst M. Phipps now forecasts that the company will earn ($0.32) per share for the quarter, up from their prior forecast of ($0.52). The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.75) per share. William Blair also issued estimates for NewAmsterdam Pharma's Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.54) EPS.

NAMS has been the topic of a number of other research reports. Royal Bank Of Canada upped their price target on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an "outperform" rating in a research note on Thursday. Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price target on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. The Goldman Sachs Group began coverage on shares of NewAmsterdam Pharma in a research note on Thursday, July 17th. They issued a "neutral" rating and a $27.00 price target on the stock. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $41.20.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $25.31 on Monday. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of -15.62 and a beta of -0.02. The firm's 50-day moving average is $20.73 and its 200 day moving average is $19.98. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.37. The firm had revenue of $19.15 million for the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%.

Hedge Funds Weigh In On NewAmsterdam Pharma

Institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after purchasing an additional 596 shares during the period. Legal & General Group Plc lifted its stake in shares of NewAmsterdam Pharma by 24.8% in the 4th quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock worth $590,000 after purchasing an additional 4,556 shares during the period. Northern Trust Corp bought a new position in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $556,000. Barclays PLC lifted its stake in shares of NewAmsterdam Pharma by 120.0% in the 4th quarter. Barclays PLC now owns 16,713 shares of the company's stock worth $429,000 after purchasing an additional 9,117 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $784,000. Institutional investors own 89.89% of the company's stock.

Insider Activity

In other news, COO Douglas F. Kling sold 100,000 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $19.29, for a total value of $1,929,000.00. Following the transaction, the chief operating officer owned 44,000 shares in the company, valued at $848,760. This represents a 69.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James N. Topper acquired 8,584 shares of the stock in a transaction dated Monday, June 16th. The stock was acquired at an average price of $19.50 per share, for a total transaction of $167,388.00. Following the purchase, the director directly owned 3,022,153 shares in the company, valued at approximately $58,931,983.50. This trade represents a 0.28% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 12,364 shares of company stock worth $236,839 and have sold 198,612 shares worth $4,025,887. 20.84% of the stock is currently owned by corporate insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.